PHARMACEUTICAL PREPARATION AND METHOD FOR TREATMENT OF DIABETES

Abstract: The use of at least one isoform of sulfatide for the production of a pharmaceutical preparation for treatment of a diabetic condition is disclosed. Also a method for treatment of a diabetic condition, wherein a therapeutically effective amount of at least one isoform of sulfatide is administered to a patient, wherein said at least one isoform of sulfatide upon administration to the patient affects the sulfatide metabolism in such a way that it results in an increased amount of sulfatide. Said isoform is preferably an isoform with 8 - 24 carbon atoms in the fatty acid chain, more preferably 14 - 18 carbon atoms, and most preferably 16 carbon atoms.

Description: PHARMACEUTICAL PREPARATION AND METHOD FOR TREATMENT OF DIABETES Field of the invention The present invention relates to new pharmaceutical preparations and methods for treatment of diabetes, in particular diabetes type 2. Background of the invention Diabetes is a very common disease in which the body does not produce any or enough insulin or does not properly use insulin. There are two major types of diabetes: diabetes type 1, or insulin-dependent diabetes mellitus (IDDM) , in which the body does not produce any insulin, most often occurring in children and young adults and regarded as an autoimmune disease; and diabetes type 2, noninsulin-dependent diabetes mellitus (NIDDM) the most common form of the disease, which is a metabolic disorder resulting from the body's inability to make enough, or properly use, insulin. Diabetes type 2 accounts for approximately 90% of all cases of diabetes. It is also a very common disorder, affecting 2-10% of the population in the Western world. The causes of diabetes type 2 are not completely known, though both genetic and environmental factors, such as obesity and lack of exercise, appear to play roles. There is also a form of diabetes that women may develop during pregnancy, gestational diabetes, and a form of autoimmune diabetes with starts in adulthood, which is called LADA (latent autoimmune diabetes in adults) or slowly progressing autoimmune diabetes. Diabetes type 1 is generally treated with insulin. Other possible ways to treat in particular diabetes type 1 have been described i.a. in WO 92/19633, which relates to the use of sulfated glycolipids, WO 97/42974, which relates to the use of glycolipid complexes, and WO 99/33475, which relates to the use of galactosylceramide, glucosylceramide, and lactosylceramide . Also transplantation of pancreas or insulin producing pancreatic cells has been tested. Diabetes type 2 is normally first treated with special diets, and if this is not enough then generally treated with one of three different types of drugs; either a drug that stimulates the release of insulin from pancreas, or a drug that increases the patient's sensi- tivity to insulin, or a drug that directly affects the blood level of glucose (such as drugs decreasing the production of glucose form the liver or drugs increasing the uptake of glucose into muscles) . These drugs may also be used in combination with different diets. In many cases also insulin is used. None of the current treatment strategies is applicable with optimal results for all diabetic patients and there is thus a great demand for efficient ways to treat diabetes, and especially diabetes type 2. Summary of the invention The object of the invention is thus to provide a new way to treat diabetes, particularly diabetes type 2. In the work leading to the present invention it was found that sulfatide is an important substance in the prevention and treatment of diabetes, and especially diabetes type 2. The invention thus relates to the use of at least one substance that upon administration to a patient will affect the sulfatide metabolism in a way that leads to an increased amount of sulfatide, or, more precisely, at least one molecular species or isoform of sulfatide, for the production of a pharmaceutical preparation for treatment of a diabetic condition, wherein said substance is an isoform of sulfatide. The invention also relates to a method for treatment of a diabetic condition, wherein a therapeutically effec- tive amount of a substance that upon administration to a patient affects the sulfatide metabolism in such a way that it results in an increased amount of sulfatide, or more precisely, at least one molecular species or isoform of sulfatide, wherein said substance is an isoform of sulfatide . The diabetic conditions that may -be treated according to the present invention includes pre-diabetes , diabetes, glucose intolerance and complications associated with diabetes. The diabetes treatable according to the present invention includes diabetes type 1, diabetes type 2, LADA and gestational diabetes. Furthermore, it was found that specific isoforms, namely the isoforms with 8 - 24 carbon atoms, and more particularly the isoforms with 14 - 18 carbon atoms and most particularly the isoform with 16 carbon atoms, in the fatty acid chain lead to an increased uptake of sulfatide. According to preferred embodiments of the invention, the substance used for the production of the phar- maceutical composition or in the method is thus the isoforms with 14 - 18 carbon atoms in the fatty acid chain, and most preferably the one with 16 carbon atoms in the fatty acid chain. The pharmaceutical composition produced according to the invention and the method according to the invention are thus suitable for treatment of a diabetic condition, such as prediabetes, diabetes and/or a complication associated with diabetes. The characterising features of the invention will be evident from the following description and the appended claims . Brief description of the drawings In the detailed description and the examples below, reference is made to the accompanying drawings on which: Fig. 1 is a schematic illustration of a sulfatide molecule ; Fig. 2 illustrates the metabolism of sulfatide; Fig. 3 is an autoradiogram revealing a lipid moiety difference between sulfatide from Lewis rats and the Ob/Ob mice; Fig. 4 illustrates that there are two major analogues, one with C24:0 fatty acid and one with C16:0 fatty acid in islets of Langerhans from pancreas of Lewis rats and BB rats, and that the C16:0 analogue is reduced to undetectable concentration in the two type 2 mice models ob/ob and db/db (as studied with TLC-ELISA using a anti-sulfatide monoclonal antibody) ; Fig. 5 illustates that the isoform of sulfatide with 16 carbon atoms in the fatty acid has a significant effect on the preservation of insulin crystals as compared to the C24 analogue and to native sulfatide, as well as to insulin stored without sulfatide; Fig. 6A illustrates the uptake of different sulfatide isoforms in liver; and Fig. 6B illustrates the uptake of different sulfatide isoforms in pancreas. Detailed description of the invention As stated above, the inventors have found that sulfatide is an important substance in prevention of diabetes, and especially diabetes type 2. Sulfatide, or galactosylceramide-3-O-sulfate, is an acidic glycosphingolipid. A schematic illustration of the sulfatide molecule is shown in figure 1. As seen in the figure, the sulfatide molecule comprises a sulfated ga- lactose, a sphingosine base, and a fatty acid. A variety of molecular species of sulfatide, or sulfatide isoforms, have earlier been described, and they differ from each other in the number of carbons present in the fatty acid and in the degree of unsaturation and hydroxylation. The different sulfatide isoforms have, to some extent, different biological activities. Furthermore, some cases of diabetes type 2 may be due to lack of a specific molecular species, or isoform, of sulfatide, and it may then be important to perform the treatment according to the invention in such a way that an increased amount of this specific molecular species is obtained. According to the present invention it is possible to use all different isoforms of sulfatide, both naturally occurring and synthetic. According to the invention the use of sulfatide isoforms with 8 - 24, preferably 14 - 18 and most preferably 16 carbon atoms in the fatty acid chain are preferred, and especially the sulfatide isoform with 16 carbon atoms in the fatty acid chain, since this isoform leads to the best uptake of sulfatide, as illustrated further in the examples below. Sulfatide is produced in the insulin producing cells in a variety of mammalian species, including man and the isoform specific for these cells. The fact that sulfatide is processed through the same intracellular route as insulin further supports the findings according to the invention. Sulfatide is involved in normal processing of insulin, from pro- insulin to secreted monomeric insulin. It is involved in the folding and oxidation of proinsu- lin, and is thus required for insulin formation, it is involved in the preservation of insulin crystals in secretory granules, and is thus required for the storage of the insulin pool, prevents detoriation and fibril forma- tion, and it is involved in the transformation of insulin from hexamer via dimer to monomer form at secretion, and this last conversion to monomer is required for biological activity. Furthermore, sulfatide might be needed in combination with insulin in order to affect the insulin receptors in a proper way and to avoid development of insulin resistance. The inventors of the present invention have found that sulfatide in combination with insulin in- hibited the T-cell response to insulin supporting that sulfatide and insulin are normally complexed in the circulation and as such does not induce immune response seen in diabetes type 1 patients and in response to exoge- nously administrated insulin. An altered sulfatide synthesis is thus a pathogenic factor involved in diabetes, both diabetes type 1 and diabetes type 2. The inventors have for example shown that a deficient sulfatide metabolism is associated with insulin deficiency (this is further illustrated in the example) as well as in insulin resistance in diabetes type 2. Sulfatide metabolism occurs i.a. in the Golgi complex of islets of Langerhans in pancreas. A schematic il- lustration of the sulfatide metabolism is shown in figure 2. As seen in the figure, this metabolic pathway involves several steps. In order to obtain the result desired according to the present invention, i.e. to obtain an increased amount of at least one molecular species of sul- fatide, it is possible to affect this pathway by affecting the level of the end product sulfatide. This may be done. It is possible to affect the level of sulfatide by the administration of an isoform of sulfatide, or functionally equivalent analogues thereof. The isoform may be either one of or a combination of the isoforms wherein the fatty acid part comprises 8 - 24, preferably 14 - 18 and most preferably 16 carbons, or functionally equivalent analogues thereof, and, as stated above and further commented on below, in some cases it may be preferable to administer one specific molecular species or isoform of sulfatide, i.e. an isoform with a specific number of carbons. The expression "treatment" used herein relates to both prophylactic treatment, i.e. treatment in order to cure or alleviate a disease or a condition, and to therapeutic treatment, i.e. treatment in order to prevent the *ϋ 3 SD φ SD SD Ω SD SD SD rt rt < i C rt CO rt SD rt 3 rt CQ rt X 3 SD Φ CQ X 3 3 O 3 3 H| tr X φ Φ CO X 3 μ- 3 μ- ra Φ 3 0 3 SD Φ 3 rt SD P. HI Pi V Φ Φ Φ 3 CQ φ Φ X-x 0 SD φ X Ω rt 3 X, < O SD * £ 3 * ~^-. \ X-x ft μ- Pi Hi 3 SD X-x Pi rr X rt SD Φ Hi tr Φ TS o 0 Ό φ s; SD Ό Hi CQ SD 3 X-x CD X 3 Φ Φ t "1 0 H X-x H| HI 3 H Hi Φ s Hi 0 H φ tr H SD rt SD X 1-3 • T3 < n Φ H μ- 0 SD X-x t X-x φ IP t φ tr i— ■ 3 0 3 t i Φ tr 3 μ- X-x Φ X Φ H O ^ rt <τ) rr w μ- rt Φ CQ Φ i— ■ μ- Pi Φ Hi Φ φ P 0 rt HI Φ Hi φ μ- Hi Φ tr 3 H- H- CQ CQ SD tr 3 HI rt Φ 3 c: 3 rt φ Φ IP X φ CQ 3 Φ φ O 3 CQ φ φ Φ 0 TJ H| < π μ- Ω SD Ό tr μ- Φ φ Hi 3 Φ μ- Φ 0 i < 3 Φ Hi 3 CQ CD SD tr <! X 3 CQ rt • ; t Φ 3 X Hh μ- 3 Φ 3 £ 3 μ- Φ 0 rt rr X X Pi rt rt rt SD SD SD o rt μ- SD Hi *ϋ Hi CQ 3 CQ ti CD SD 3 3 Ti tr H- Ξ CQ SD φ μ- 0 3 X Hi rt HI • s: H| 0 SD Hi SD Hi Hi Φ Ω 0 SD H| Hi tr rt Hi Φ 0 CQ CD j SD CQ φ Φ 3 μ- 3 3 SD D X-x 3 13 Φ φ Ω rt rt Hi 3 φ Φ SD Φ μ- X Φ Hi CQ H{ SD T3 Hi φ Pi 3 SD <: SD rt CQ SD Φ X-x CQ rt X μ- Φ X-x CD > ** . rt 0 3 CD • n 3 Φ CQ rt SD μ- rt μ- Ω Φ Ω rt μ- 0 0 Ω c SD CQ 3 0 ≤ SD CD Φ φ 3 3 O Φ SD Φ CQ CD CQ SD 3 φ CO Φ 0 0 Hi Φ rt rt μ- 0 CD 3 μ- tr rt μ- CD SD μ- H{ CD O fl ) φ tr 0 < 3 • c 3 Ω s^ μ- Φ 0 3 SD rt μ- Φ 0 3 3 0 Hi P Hi X Ω 3 CQ Φ Hi Φ rt rt 3 rt 0 rt Ω CQ 3 SD X-x X o CO 3 0 SD H 3 0 μ- H| rt μ- X-x P rt 3 μ- μ- SD 0 3 μ- SD μ- X-x X-x rt 3 X 3 Hi o 0 ι-i SD X-x SD Φ Pi rt Ω Ω 3 Hi φ <V Ω rt -: 3 CQ • ^ 3 0 rt Φ SD ϊ 3 φ 3 SD rt 3 tr Hi CQ μ- μ- SD SD Hi SD 0 rt CO 3 IP 0 Hh Ω 3 O φ SD Ω Φ CQ 1— ' Hi • Hh o h- ' X-x CQ rt < τi μ- X-x Φ X 3 tr Φ rt μ- 3 0 0 Φ 3 SD P. CQ O rt & ft 0 Φ Hi 3 X-x ? tr Hi CQ Hi SD Φ X-x CQ Λ X Ω SD 3 3 Hi X SD rt φ X Φ H| W 0 Ω φ • X, μ- Φ φ φ •n Hi 3 Hi rt 3 Φ SD Ω CO *ϋ X-x μ- \ s; fl) p. rt 3 Hi SD H| I—' O Hi Φ SD 3 SD X-x CD rt μ- IP Hi Φ 3 0 o μ- rt SD μ- Ω Φ Hi Φ SD X-x Ό D to Φ Ω SD Ό 3 < 3 3 μ- Pi X-x φ μ- 3 Hi r Hi rt CD < • . 3 3 Φ *ϋ Ω φ Hi Hi c Ό rt 3 φ SD Ω SD Φ φ tr 0 Φ 3 CO 3 rt SD H X CQ Φ Q rt SD Ω Pi Φ SD tr SD • 0 3 CQ Φ u Hh CQ 3 Hi Ω CO - 3 3 0 I— i CQ SD SD HI Φ T3 rt CQ H| C rt Φ 3 Hh rt SD Φ 0 3 H- 3 rt φ CQ Φ Kl X-x SD <τi μ- SD μ- rr SD 3 μ- rt rt 3 μ- φ SD X-x α CD 0 Φ 3 SD Ω Ω 3 X Φ CQ μ- CQ rt rt 3 Hi 0 SD rt rt Ω 3" 3 ^ rt 3 Ω 3 X-x Φ 3 Φ CO Ω 0 (D CQ i h- ' Φ 0 CD 0 μ- SD SD in 3 μ- SD Φ SD IP rt Ω ^ SD Pi Φ 3 3 CQ 3 rt CQ Ω φ 0 tr rt rt Ω 0 rt H- 1 rt SD Φ CD μ- SD rt SD P SD CQ 3 X-x tr μ- μ- Φ 3 tr X-x CQ 3 0 SD Φ α> 3 X-x 0 Φ μ- 3 μ- & ) μ- SD CQ 3 φ Φ 0 rt CQ SD ^ 3 s; SD Hi CQ rt lP O rt CQ Hi tr rt rr 3 Q rt φ μ- SD 3 SD rt X-x μ- X-x X 3 SD 0 0 Φ 0 μ- ω φ Φ CQ rt 3 SD SD CQ c Ω Φ Hi x- χ 0 rt rt SD μ- rt X-x rt Hi Hi o tr 1 Φ SD P. SD Hi Φ CQ Ω • s; Hi SD X-x IP tr X rt <! μ- Φ Hi Φ n 3 (D CD l-h CQ 3 SD tr L_l. rt X-x Φ 0 Hi r 3 Φ Φ D Φ H( 3 Φ μ- μ- • s; CD μ- φ Φ Pi CQ ft c C Hi Hi X-x Φ μ- X Φ £ X-x 3 SD Ω SD 3 3 i- * μ- Ω CO "<. μ- CQ φ tr < Ω •• P- X-x Ω SD Ό CQ μ- φ rt 3 X-x rt H CQ (- * Ω μ- • CQ CQ 0 Φ SD SD t rt μ- rt Φ < 0 HI 3 x- χ 3 CD Ω 3 3 Hi SD 3' μ- Φ φ Ω Hh 3 3 0 O P X-x μ- Φ Hi φ tr X-x rt Φ S^ Φ φ Φ H| H- φ 3 SD SD 0 3 rt Pi CQ Hi UQ φ < μ- CQ CQ μ- Φ 3 X-x Ω SD CQ 3 rt 3 CQ SD Hi Φ CQ c Hi SD φ ω Φ SD Φ rt X SD 3 CQ rt SD tr rt rr 0 Ω Φ ft rt - 3 tr Hh SD rt 0 CD 3 3 SD SD 3 SD rt H| CQ ^ ω CQ Φ TJ X SD CQ SD Ω 0 D 3 CQ rt 3 < SD 0 X- 1 SD • Ό SD Φ 0 φ 3 3 Hi 0 Ω rt Ω μ- rt 3 φ Φ μ- Ω φ h- 1 rt rt φ Ω CQ 3 SD rt x— χ φ 3 Φ P SD SD μ- rt 0 o HI 3 CQ H- φ 0 3 J tr Hi Ω μ. rt H CD Hi ii SD • s < HI Hi 3 X-x 13- 3 rt O 3 φ IP Φ 0 CQ O rt Ω 3 1^ SD μ- Φ SD Hi 0 Ω μ- rt Φ rt 3 μ- 3 < μ- CQ 3 Hi 3 0 Hi 0 Φ Φ rt φ rt 3 Ω μ- Hi Φ rt SD X rr SD φ Φ rt CQ Φ CQ l-h μ- 3 Pi Ξ μ- 3 CD Hi X rt φ CQ SD rt Φ - X-x Hi 3 Φ - Ω X CQ μ- SD SD rt HI - 0 μ- HI Φ rt Φ 3 X-x μ- 3 0 0 Φ 3 3 • * ! HI 0 CQ X Φ ^ 0 CQ 3 3 IP "< 3 Hi lipid extracts were separated and analysed by thin-layer chromatography combined with immunohistochemical analyses using a sulfatide specific monoclonal antibodies. Sulfatide standards of known amounts were analysed in parallel to allow quantification. The obtained quantitative values for sulfatide in islet cells from the mice are shown in Table 1 below. The results showed a marked reduction of the total amount of sulfatide in the islets from the diabetes type 2 model . Table 1 Islets cell isolated from pancreatic tissue from Ob/Ob mice and Lewis rats were grown in media containing 35 S-sulfate. The lipids were then extracted, separated and analysed autoradiography after chromatography on silica gel thin layer plates . Figure 3 shows the autoradiogram and reveal a lipid moiety difference between sulfatide from Lewis rats and the Ob/Ob mice, a diabetes type 2 model . Example 2 - Studies on the uptake of sulfatide in pancreas and liver in ob/ob mice after intraperiotenal injection ( 3 H) This example illustrates that the sulfatide isoform with a fatty acid chain having 16 carbon atoms optimises the uptake of sulfatide and the insulin processing. In this example the expression "Cn:x analogue" de- notes the isoform of sulfatide with n carbon atoms and x double bonds, for instance the C8 : 0 analogue is thus the isoform of sulfatide with 8 carbon atoms and no double bonds in its fatty acid chain. Background Ob/ob mice have by biochemical analyses been shown to have an aberrant sulfatide metabolism, both quantita- tively and qualitatively (see Example 1) . Sulfatide is a sulfated glycosphingolipid in which the composition of the lipid moiety may vary. In islets of Langerhans from pancreas of Lewis rats and BB rats there are two major analogues, one with C24 : 0 fatty acid and one with C16 : 0 fatty acid. In the two type 2 mice models ob/ob and db/db the C16:0 analogue is reduced to undetectable concentration (as studied with TLC-ELISA) using a anti-sulfatide monoclonal antibody. This is shown in Figure 4. The inventors have performed in vitro studies that reveals that the C16:0 analogue is important for the insulin processing. The preservation of insulin crystals, a requirement for storage of an insulin pool that can be released upon raised blood glucose, is increased for sulfatide C16:0 compared to other sulfatide isoforms. The C16:0 analogue of sulfatide has a significant effect on the preservation as compared to the C24 : 0 analogue and to native mixture of sulfatide from pig brain, as well as to insulin stored without sulfatide. This is illustrated in Figure 5. Hypothesis The lack of C16 : 0 analogue of sulfatide in islets of Langerhans of the diabetes type 2 models leads to non- optimal insulin processing. This might effect not only insulin deficiency but also insulin resistance. Restoration of the presence of C16 : 0 sulfatide in the islets by providing C16 : 0 sulfatide is thus a strategy to treat diabetes type 2. Experimental design Native sulfatide isolated from pig brain and structurally characterised by mass spectrometry was modified with regard to the fatty acid composition and tritiated in the sphingosine base. These analogues were administrated intraperiotenally to diabetic ob/ob mice and their uptake in liver and pancreas analysed after lipid extrac- tion of dissected organs. The aim was to explore whether the exogenously administrated sulfatide was taken up by pancreas and thereby open a possibility to substitute for the quantitative and qualitative alterations of sulfatide seen in the diabetes type 2 models. Radiolabelling of sulfatide Sulfatide was tritium labelled in the ceramide portion by catalytic hydrogenation with Pd (OAc) 2 /NaB 3 H 4. The labelled sulfatide was mixed with unlabelled sulfatide to the required specific activity. Modification of the fatty acid moiety in sulfatide The fatty acid was removed from native pig brain sulfatide by weak alkaline methanolysis at 80°C. The formed lysosulfatide was, after chromatographic purification, reacylated with respective fatty acid chloride in aqueous sodium acetate-tetrahydrofuran. Administration of radiolabelled sulfatide analogues to ob/ob mice The different sulfatide analogues, as shown in Table 2, were dissolved in phosphate buffered saline, 150 nmol/300 μL, (the samples were sonicated for 20 s) and then administrated i.p. to ob/ob mice. These mice were 12 weeks old and the mean value of the highest blood glucose was 13.4 ± 1.3 nM. At sacrifice the mice were anaesthetised with C0 2 and killed by dislocation of the neck vertebrae. This is outlined in Table 2. The liver and pancreas were dissected immediately. The organ were quick- frozen and thawed at analyses (within 4 days) . Table 2 Sulfatide extraction and analyses The organs were homogenised and the lipids extracted with chloroform/methanol/water . The lipid extracts were evaporated, re-dissolved in chloroform/methanol/water and separated by silica gel chromatography to remove other lipids. The sulfatide containing fraction was used for counting by scintillation. The results of the scintillation measurement are presented in Figure 6A and Figure 6B - Figure 6A presenting liver data and Figure 6B pancreas data - as cpm uptake in total, cpm/mg wet weight of tissue, cpm/mg of tissue protein and % of given cpm residing in the organ The C8 : 0 analogue was preferentially taken up in liver and was rapidly degraded. In pancreas its uptake was much lower than for the other two analogues. The 6 hour and 24 hour value were similar and thus neither ac- cumulation or degradation was noticed. The C24:0 analogue showed a lower uptake in liver as compared to the C8 : 0 analogue. There was a slight reduction of C24 : 0 in both organs at 24 hour indicating a slow degradation and no accumulation. The C16:0 analogue uptake in the liver was higher than for the C24:0 and also showed a slight accumulation. In comparison to the C8 : 0 analogue the liver uptake at 6 hours after administration was lower but in contrast to the finding with the C8 : 0 sulfatide, which was rapidly degraded, the C16:0 showed an accumulation at 24 hours. In pancreas the C16:0 sulfatide analogue was that most efficiently taken up and there was, like in liver, an accumulation after 24 hours. Conclusion The uptake of sulfatide varied between the analogues with different fatty acid composition. Among these the shortest C8 : 0 is rapidly removed from circulation to the liver and degraded . Moreover there was relatively uptake in pancreas and no accumulation. Both C16 and C24 analogues were efficiently taken up in pancreas but while C24 showed a slight degradation during the 24 hour period there was an accumulation of the C16 analogue. Thus, pancreas seems to have a selected uptake of the analogue of sulfatide that has been shown to be lacking in the diabetes type 2 models and thus the inventors have shown that administration of sulfatide, and especially the administration of the sulfatide isoform with 16 carbon atoms in the fatty acid is one way to restore the aberrant metabolism of this molecule.

Claims: CLAIMS 1. Use of at least one isoform of sulfatide for the production of a pharmaceutical preparation for treatment of a diabetic condition. 2. Use according to claim 1, wherein said diabetic condition is pre-diabetes, diabetes, glucose intolerance and/or a complication associated with diabetes. 3. Use according to claim 1 or 2 , wherein said dia- betes is diabetes type 1, diabetes type 2, LADA and/or gestational diabetes. 4. Use according to claim 3, wherein said condition is diabetes type 2. 5. Use according to any one of the claims 1 - 4, wherein at least one isoform of sulfatide has 8 - 24 carbon atoms in its fatty acid chain. 6. Use according to any one of the claims 1 - 5, wherein at least one isoform of sulfatide has 14 - 18 carbon atoms in its fatty acid chain. 7. Use according to any one of the claims 1 - 6, wherein at least one isoform of sulfatide has 16 carbon atoms in its fatty acid chain. 8. Use according to any one of the claims 1 - 7, wherein said at least one isoform of sulfatide comprises no double bonds in its fatty acid chain. 9. Use according to any one of the claims 1 - 4, wherein only one isoform of sulfatide is used. 10. Use according to claim 9, wherein said isoform of sulfatide has 8 - 24 carbon atoms in its fatty acid chain. 11. Use according to claim 9 or 10, wherein said isoform of sulfatide has 14 - 18 carbon atoms in its fatty acid chain. 12. Use according to any one of the claims 9 - 11, wherein said isoform of sulfatide has 16 carbon atoms in its fatty acid chain. 13. Use according to any one of the claims 9 - 12, wherein said isoform of sulfatide comprises no double bonds in its fatty acid chain. 14. Use according to any one of the claims 1 - 13, wherein at least one isoform of sulfatide is a naturally occurring isoform. 15. Use according to any one of t*he claims 1 - 13, wherein at least one isoform of sulfatide is a synthetically produced substance. 16. Use according to any one of the claims 1 - 15, wherein said pharmaceutical composition is formulated for oral administration. 17. A method for treatment of a diabetic condition, wherein a therapeutically effective amount of at least one isoform of sulfatide is administered to a patient, wherein said at least one isoform of sulfatide upon administration to the patient affects the sulfatide metabolism in such a way that it results in an increased amount of sulfatide. 18. A method according to claim 17, wherein said diabetic condition is pre-diabetes, diabetes, glucose intolerance and/or a complication associated with diabetes. 19. A method according to claim 17 or 18, wherein said diabetes is diabetes type 1, diabetes type 2, LADA and/or gestational diabetes. 20. A method according to claim 19, wherein said diabetes is diabetes type 2. 21. A method according to any one of the claims 17 - 20, wherein at least one isoform of sulfatide has 8 - 24 carbon atoms in its fatty acid chain. 22. A method according to any one of the claims 17 - 21, wherein at least one isoform of sulfatide has 14 - 18 carbon atoms in its fatty acid chain. 23. A method according to any one of the claims 17 - 22, wherein at least one isoform of sulfatide has 16 carbon atoms in its fatty acid chain. 24. A method according to any one of the claims 17 - 23, wherein said at least one isoform of sulfatide comprises no double bonds in its fatty acid chain. 25. A method according to any one of the claims 17 - 20, wherein only one isoform of sulfatide is administered. 26. A method according to claim 2-5, wherein said isoform of sulfatide has 8 - 24 carbon atoms in its fatty acid chain. 27. A method according to claim 25 or 26, wherein said isoform of sulfatide has 14 - 18 carbon atoms in its fatty acid chain. 28. A method according any one of the claims 25 - 27, wherein said isoform of sulfatide has 16 carbon atoms in its fatty acid chain. 29. A method according any one of the claims 25 - 28, wherein said isoform of sulfatide comprises no double bonds in its fatty acid chain. 30. A method according to any one of the claims 17 - 29, wherein at least one isoform of sulfatide is a naturally occurring isoform. 31. A method according to any one of the claims 17 - 29, wherein at least one isoform of sulfatide is a synthetically produced substance. 32. A method according to any one of the claims 17 - 31, wherein said isoform of sulfatide is administered orally.

Inventors: BUSCHARD KARSTEN, FREDMAN PAM, BUSCHARD, KARSTEN, FREDMAN, PAM
Applicants: A & SCIENCE INVEST AB, BUSCHARD KARSTEN, FREDMAN PAM, A+ SCIENCE INVEST AB, BUSCHARD, KARSTEN, FREDMAN, PAM
Application year: 2001
Main classification: A61K31
IPC codes: A01N43, A61K31, A61P3, A61P15